Table 2.

HRPC patients background and therapeutic response to taxane-based chemotherapy

Patient no.Age (y)Response to chemotherapy
PSA (% decrease)Lymph nodeLiverBonePrimary siteOverall response
17890.6(−)(−)SDResponse (+)PR
26488.3(−)(−)SDResponse (+)PR
37885.1PR(−)SDResponse (+)PR
48097.3PR(−)(−)Response (+)PR
57096.0SD(−)SDResponse (+)SD
66999.8(−)(−)SDResponse (+)PR
77595.5SD(−)SDResponse (−)PD
86598.3(−)(−)SDNo changePR
97690.2(−)(−)SDResponse (+)PR
106699.3(−)(−)SDResponse (+)PR
118099.3(−)(−)SDNo changePR
126293.8PR(−)SDResponse (+)PR
136387.0SD(−)SDResponse (+)SD
147683.6PR(−)SDResponse (+)PR
157281.9(−)(−)(−)Response (+)PR
167668.3SD(−)SDNo changeSD
176790.1PRPRSDResponse (+)PR
187660.5SD(−)PRNo changeSD
197595.5(−)(−)SDResponse (+)PR
207394.2(−)(−)SDResponse (+)PR
217792.0PR(−)SDResponse (+)PR
227355.9SD(−)SDResponse (+)SD
237187.7(−)(−)SDNo changePR
246597.2PR(−)SDResponse (+)PR
257991.8PR(−)(−)Response (+)PR
267051.0PR(−)SDResponse (+)SD
277256.0(−)(−)SDResponse (+)SD
286952.0(−)(−)(−)Response (+)SD
297198.9SD(−)SDNo changePR
307351.0(−)(−)SDResponse (+)SD
  • Abbreviations: CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease; (−), no metastatic lesions detected.